TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2904371
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral capsule formulation of temazepam
Study: 31641948
Drug: Polymorphonuclear neutrophil
Normalized name: Polymorphonuclear neutrophil elastase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphonuclear neutrophil (PMN) count (> 6000/mm3 vs. ≤ 6000/mm3) before chemotherapy
Study: 31641948
Drug: FOLFOX-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-based chemotherapy regimen
Study: 25495134
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg and famotidine 26.6 mg
Study: 16893694
Drug: Biolimus A9
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biolimus A9 drug-eluting stent
Study: 15082989
Drug: Oxycodone or
Normalized name: oxycodone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone or hydrocodone
Study: 8222513
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin infusion
Study: 3951807
Drug: Half-dose Amicar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose Amicar (50 mg/kg every four hours for five days, up to a maximum of 30 g/day)
Study: 3951807
Drug: Full-dose Amicar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose Amicar (100 mg/kg every four hours, up to a maximum of 30 g/day)
Study: 3951807
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Half-dose and Full-dose)
Study: 3951807
Drug: Both dose
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dose levels of Amicar
Study: 3951807
Drug: Prior aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior aspirin ingestion
Study: 29557487
Drug: Control (Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Tramadol hydrochloride tablets)
Study: 29750367
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (2 g daily)
Study: 25649051
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg OPC
Study: 25649051
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg OPC
Study: 25649051
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg OPC
Study: 25012176
Drug: rt-PA/heparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA/heparin (1 mg per lumen, once per week)
Study: 25012176
Drug: heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin alone (thrice-weekly)
Study: 25012176
Drug: rt-PA/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA/heparin
Study: 19523170
Drug: Pseudocatalase cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudocatalase cream with NB‐UVB
Study: 17035933
Drug: Continuous paroxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous paroxetine treatment
Study: 17035933
Drug: Intermittent paroxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent paroxetine treatment (luteal phase only)
Study: 16304269
Drug: IV azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV azithromycin plus IV ceftriaxone followed by oral azithromycin
Study: 16304269
Drug: IV levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV levofloxacin followed by oral levofloxacin
Study: 1643914
Drug: Pulsed-release albuterol
Normalized name: albuterol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed-release albuterol sulfate (8 mg)
Study: 6383749
Drug: Gentamicin 2.4
Normalized name: gentamicin 2.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 2.4 mg/kg at 12‐ or 18‐hour dosing intervals
Study: 29374469
Drug: Propofol/remifentanil (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/remifentanil (4-6 mg/kg/h)
Study: 27310330
Drug: PTC299 (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC299 (0.03 to 3 mg/kg single dose)
Study: 27310330
Drug: PTC299 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC299 (0.3 to 1.2 mg/kg twice a day or 1.6 mg/kg 3 times a day for 7 days)
Study: 22404324
Drug: Levofloxacin (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (therapeutic dose 750 mg)
Study: 22404324
Drug: Levofloxacin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (low dose 7.5 mg)
Study: 22404324
Drug: Cyclosporine (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (therapeutic dose 200 mg)
Study: 22404324
Drug: Cyclosporine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (low dose 2 mg)
Study: 12856809
Drug: Compound Nylestriol
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Nylestriol Tablet (CNT) - 0.5 mg nylestriol and 0.15 mg levonorgestrel, one tablet per week for one year
Study: 7851278
Drug: Buprenorphine (high-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (high-dose, 3 day regimen)
Study: 2682412
Drug: Patient-controlled administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled administration of 10 mg meperidine every 20 minutes
Study: 2682412
Drug: Nurse-administered meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered meperidine (25-50 mg every 3 hours as requested)
Study: 2682412
Drug: Patient-controlled administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled administration of meperidine
Study: 338400
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg daily of maprotiline (Ludiomil) administered once or thrice daily
Study: 338400
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg daily of maprotiline (Ludiomil) administered once or thrice daily
Study: 338400
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg three times daily of maprotiline (Ludiomil)
Study: 338400
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg thrice daily of maprotiline (Ludiomil)
Study: 338400
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nocte of maprotiline (Ludiomil)
Study: 31915160
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg lithium carbonate
Study: 25855884
Drug: Calfactant administration
Normalized name: Calfactant
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calfactant administration
Study: 23765945
Drug: B-vitamins (folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamins (folic acid, 2 mg; vitamin B6, 25 mg; vitamin B12, 500 μg)
Study: 21147261
Drug: Warfarin continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin continuation
Study: 21147261
Drug: Warfarin interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin interruption
Study: 8174496
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 g q 8 h i.v.)
Study: 28576557
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care with saline heparin locks (Control)
Study: 22320849
Drug: Baseline oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline oral health-related knowledge, attitudes, and beliefs regarding caries control.
Study: 15996346
Drug: Allergy Guard
Normalized name: Clinda-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergy Guard (topical cream containing zinc gel)
Study: 10343146
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d. and amoxicillin 1,000 mg b.i.d. for 7 days
Study: 6807149
Drug: DSGN nebulized
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSGN nebulized solution
Study: 25119950
Drug: Varilrix(®) +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varilrix(®) + cyclosporine (2.5 mg/kg/day)
Study: 25119950
Drug: Subcutaneous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous saline + cyclosporine (2.5 mg/kg/day)
Study: 17919215
Drug: 0.1 mL
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL intradermal 1% lignocaine
Study: 15449549
Drug: Octreotide administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide administration
Study: 9745451
Drug: Spironolactone (MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (MR antagonist)
Study: 9745451
Drug: Spironolactone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (two doses)
Study: 7836162
Drug: 10% glucose
Normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glucose solution containing 6‐[3H]glucose (CHO)
Study: 2831524
Drug: Atenolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (10 mg IV every six hours for three days, then 100 mg orally once a day for four days)
Study: 23090678
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg daily oral ibandronate (n = 40)
Study: 23090678
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intermittent oral ibandronate (n = 34)
Study: 23090678
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (n = 36)
Study: 20380480
Drug: Fosamprenavir/ritonavir (FPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosamprenavir/ritonavir (FPV/r) 1400 mg/100 mg
Study: 20380480
Drug: Atazanavir/ritonavir (ATV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (ATV/r) 300 mg/100 mg
Study: 18652000
Drug: Standard pre-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pre-chemotherapy education
Study: 10832917
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 microg/kg twice a day) + Naltrexone (25 mg twice a day)
Study: 9093956
Drug: Questionnaire on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Questionnaire on visual tasks in daily living
Study: 8475558
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 infusion (PG group)
Study: 2881461
Drug: HSR-902 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSR-902 (30 mg daily for 7 days)
Study: 2881461
Drug: Butylscopolamine bromide
Normalized name: Butylscopolamine Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butylscopolamine bromide (60 mg daily for 7 days)
Study: 27142448
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (2 g/day, containing 220.2 mg of catechins)
Study: 27142448
Drug: Placebo (0.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.0 mg of catechins)
Study: 25877963
Drug: efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz 600 mg
Study: 21313892
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (0.2 mg)
Study: 11823923
Drug: Acetylcholinesterase Inhibitors
Normalized name: acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholinesterase Inhibitors (AChEI)
Study: 9817530
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with zidovudine, didanosine and zalcitabine
Study: 9817530
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with zidovudine
Study: 7711990
Drug: Epidural meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural meperidine 1 mg kg‐1
Study: 7711990
Drug: Epidural pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural pentazocine 0.3 mg kg‐1
Study: 2674395
Drug: Antimicrobial agent
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial agent delivered by an oral irrigating device
Study: 31106377
Drug: Rifampicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin plus β‐lactam antibiotics
Study: 31106377
Drug: β‐lactam antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐lactam antibiotics only
Study: 23443901
Drug: Interfascial bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interfascial bupivacaine administration
Study: 23443901
Drug: Suprafascial bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprafascial bupivacaine administration
Study: 21314871
Drug: Duloxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine treatment for fibromyalgia and CLBP
Study: 21314871
Drug: Duloxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine treatment for DPNP
Study: 17824890
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of mandibular implant overdentures delivered 1 week after surgery
Study: 17824890
Drug: Conventional mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional mandibular prostheses converted to mandibular implant overdentures 3 months after surgery
Study: 17824890
Drug: Prosthodontic maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosthodontic maintenance of the mandibular implant overdentures in the first year
Study: 10730079
Drug: Preoperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative epidural morphine 2 mg at T 6‐7 and 2 mg at L 3‐4
Study: 10730079
Drug: Continuous thoracic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous thoracic epidural infusion of 1% lidocaine (lidocaine group, n = 15)
Study: 10730079
Drug: Continuous thoracic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous thoracic epidural infusion of normal saline solution (control group, n = 15)
Study: 7357821
Drug: Elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental diet supplements
Study: 25965082
Drug: Low-dose prophylactic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prophylactic corticosteroid (PCS) starting dose 15 mg/day of prednisolone for 6 weeks (PCS-On group)
Study: 25965082
Drug: Thyroid-stimulating antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid-stimulating antibody
Study: 21279975
Drug: Standard PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PDT (10‐minute 6 mg/mq2 verteporfin infusion; treatment at 15 min; 50 J/cm2; 83 s)
Study: 21279975
Drug: Bolus PDT
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus PDT (6 mg/mq2 verteporfin infusion bolus in 1 min; treatment at 5 min; 100 J/cm2; 166 s)
Study: 8083077
Drug: Cohort 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: Three completed cycles of chemotherapy and radiotherapy
Study: 26277524
Drug: HBO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO therapy at 0.175 MPa
Study: 26277524
Drug: HBO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO therapy at 0.2 MPa
Study: 26277524
Drug: HBO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO therapy at 0.175 MPa and 0.2 MPa
Study: 21501481
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy of lower intensity with CMF
Study: 21501481
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with CAF
Study: 21501481
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy alone following surgery and/or radiation therapy
Study: 8860064
Drug: Nisoldipine therapy
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine therapy
Study: 3087307
Drug: Cefotaxime sodium
Normalized name: Cefotaxime Sodium
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime sodium at a dosage of 12 g/day
Study: 24087989
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH; nadroparin) for 1 week
Study: 24087989
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH; nadroparin)
Study: 22439781
Drug: Tigecycline (TGC)
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline (TGC) 100 mg followed by 50 mg q 12 h
Study: 22439781
Drug: Ceftriaxone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone plus Metronidazole (CTX/MET) 2 g qd plus 1-2 g daily
Study: 20733444
Drug: 20 international
Normalized name: CONDOM,INTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 international units oxytocin diluted with 26 mL saline
Study: 20733444
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL saline (placebo)
Study: 12534515
Drug: 585‐nm pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 585‐nm pulsed dye laser (PDL) treatment on one scar half
Study: 12534515
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment on the other scar half)
Study: 12534515
Drug: 585‐nm pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 585‐nm pulsed dye laser (PDL) treatment
Study: 2971274
Drug: Preservative free
Normalized name: preservative free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative free ipratropium bromide nebuliser solution
Study: 2971274
Drug: Atrovent nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrovent nebuliser solution
Study: 28404008
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (resection)
Study: 26546405
Drug: Aripiprazole 15
Normalized name: aripiprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 15 mg orally disintegrating tablet (ODT) without water
Study: 26546405
Drug: Conventional aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conventional aripiprazole 15 mg standard tablet with 240 mL water
Study: 21802823
Drug: ASA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA therapy suspended 7 days before tooth extraction (group S)
Study: 21802823
Drug: ASA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA therapy unaltered (group NS)
Study: 21802823
Drug: ASA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA therapy suspended (group S)
Study: 16936457
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy combined with intravenous edaravone administration for 7 days
Study: 11401940
Drug: Gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil 1200 mg/d
Study: 11327443
Drug: High-dose didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose didanosine
Study: 8217757
Drug: Cyclosporin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (5 mg/kg/day)
Study: 3104249
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus Misonidazole (MISO) (400 mg/m2 daily 2 to 4 hours prior to radiation therapy)
Study: 3104249
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (4600 cGy pelvis plus 1000 cGy parametrial boost)
Study: 25923150
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac 75 mg and sublingual methylcobalamin
Study: 25923150
Drug: Sublingual piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual piroxicam 40 mg and intramuscular distilled water
Study: 24308190
Drug: Acupuncture intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupuncture intervention combined with hyperbaric oxygen therapy
Study: 24308190
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hyperbaric oxygen therapy only)
Study: 16797249
Drug: Onercept 10
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 10 mg
Study: 16797249
Drug: Onercept 25
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 25 mg
Study: 16797249
Drug: Onercept 35
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 35 mg
Study: 16797249
Drug: Onercept 50
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 50 mg
Study: 12878450
Drug: Head cooling
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head cooling combined with minimal hypothermia (rectal temperature 36.5-36 degrees C) for 72 hours
Study: 12878450
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Group 1a)
Study: 8416666
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g fish oil/d (50% n‐3 fatty acids)
Study: 8416666
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g fish oil/d (50% n‐3 fatty acids)
Study: 3484505
Drug: Vaccine intervention
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine intervention (specifics not provided)
Study: 17341882
Drug: Mistletoe infusion
Normalized name: MISTLETOE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe infusion (Iscador)
Study: 3220614
Drug: Diphenhydramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (50 mg or 75 mg)
Study: 31820121
Drug: Risedronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (35 mg) with cholecalciferol (5600 IU)